Current possibilities of correcting subchondral bone resorption as a major pathogenetic factor for progressive osteoarthrosis
- Authors: Naumov AV1
-
Affiliations:
- Issue: Vol 86, No 1 (2014)
- Pages: 60-65
- Section: Editorial
- Submitted: 10.04.2020
- Published: 15.01.2014
- URL: https://ter-arkhiv.ru/0040-3660/article/view/31434
- ID: 31434
Cite item
Full Text
Abstract
The paper considers the current pathogenesis, by choosing the actual targets of pharmacotherapy with available drugs. It reflects the cytokine mechanisms responsible for lesion of the synovial membranes, cartilage, and subchondral bone. Particular emphasis is laid on the role of chondroitin sulfate, glucosamine, vitamin D3 as drugs that affect the key components of pathogenesis, including the volume of resorptive cavities in the subchondral bone.
Full Text
Современные возможности коррекции резорбции субхондральной кости как главного патогенетического фактора прогрессирования остеоартроза. - Аннотация. В статье рассматривается современный патогенез остеоартроза с точки зрения выбора актуальных мишеней фармакотерапии доступными лекарственными средствами. Отражены цитокиновые механизмы повреждения синовиальной оболочки, хряща и субхондральной кости. Особое внимание уделено роли резорбции субхондральной кости в патогенезе остеоартроза. Представлена роль хондроитина сульфата, глюкозамина и витамина D3 как препаратов, влияющих на ключевые звенья патогенеза, в том числе на объем резорбтивных полостей в субхондральной кости.×
References
- Fortin M., Stewart M., Poitras M.-E. et al. Systematic Review of Prevalence Studies on Multimorbidity: Toward a More Uniform Methodology. Ann Fam Med 2012; 10 (2): 142-151.
- Long Term Conditions Compendium of Information: Third Edition. Department of Health UK, 2012.
- Haugen I.K. Abstracts from OARSI. Osteoarthritis Cartilage 2013; 289.
- Zhang W., Nuki G., Moskowitz R.W. et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010; 18 (4): 476-499.
- Wildi L., Raynauld J., Martel-Pelletier J. et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis 2011; 70: 982-989.
- Michel B.A., Stucki G., Frey D. et al. Chondroitin 4 and 6 sulfate in osteoarthritis of the knee: A randomized, controlled trial. Arthritis Rheum 2005; 52 (3): 779-786.
- Tat S.K., Pelletier J.-P., Vergés J. et al. Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. Arthritis Res Ther 2007, 9: R117.
- Pelletier J.-P. Chondroitin sulfate may reduce total knee replacement in 12-month multicenter clinical trial in knee osteoarthritis: results from 4-year observation. EULAR, ACR 2012.